Anti-PD-L1-mIFNα promotes IP-10 release from antigen-positive tumour cells, increasing T cell infiltration, and improving effector T cell function for anti-tumour immunity. Also, it upregulates MHC class I on tumour cells, increasing the response of the antitumour CD8+ T cells. Hence, the anti-PD-L1-mIFNα moiety can be a useful method for reducing tumour resistance to PD-L1 inhibition. The gene discussed is CXCL10; the disease is neoplasm.